

CITATION REPORT

List of articles citing

Lactic acid bacteria--20 years exploring their potential as live vectors for mucosal vaccination

DOI: 10.1007/s00253-015-6498-0

Applied Microbiology and Biotechnology, 2015, 99, 2967-77.

Source: <https://exaly.com/paper-pdf/61828891/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
105	Lactobacillus plantarum displaying CCL3 chemokine in fusion with HIV-1 Gag derived antigen causes increased recruitment of T cells. 2015 , 14, 169		22
104	Advances and needs for endotoxin-free production strains. <i>Applied Microbiology and Biotechnology</i> , 2015 , 99, 9349-60	5.7	17
103	Immunomodulatory effects of Lactobacillus strains: emphasis on their effects on cancer cells. 2015 , 7, 1307-29		31
102	Cell Wall Anchoring of the Campylobacter Antigens to Lactococcus lactis. 2016 , 7, 165		21
101	Oral immunization of mice with engineered Lactobacillus gasseri NM713 strain expressing Streptococcus pyogenes M6 antigen. 2016 , 60, 527-32		17
100	Lactobacillus pentosus expressing porcine lactoferrin elevates antibacterial activity and improves the efficacy of vaccination against Aujeszky's disease. 2016 , 64, 289-300		3
99	Construction of a recombinant Lactococcus lactis strain expressing a fusion protein of Omp22 and HpaA from Helicobacter pylori for oral vaccine development. 2016 , 38, 1911-1916		15
98	Development of a simple, low-cost and eurytopic medium based on Pleurotus eryngii for lactic acid bacteria. 2016 , 6, 65		2
97	Recombinant Lactococcus lactis NZ9000 secretes a bioactive kisspeptin that inhibits proliferation and migration of human colon carcinoma HT-29 cells. 2016 , 15, 102		35
96	Intracellular and Extracellular Expression of Bacillus thuringiensis Crystal Protein Cry5B in Lactococcus lactis for Use as an Anthelmintic. 2016 , 82, 1286-94		9
95	Assessment of anti-biofilm activity and bifidogenic growth stimulator (BGS) effect of lyophilized exopolysaccharides (l-EPSs) from Lactobacilli strains. 2017 , 20, 362-371		28
94	Heterologous expression of Streptococcus mutans Cnm in Lactococcus lactis promotes intracellular invasion, adhesion to human cardiac tissues and virulence. 2017 , 8, 18-29		16
93	Phytases of Probiotic Bacteria: Characteristics and Beneficial Aspects. 2017 , 57, 148-154		28
92	New Insights on Antiviral Probiotics. 2017 ,		10
91	Gas-filled microbubbles: Novel mucosal antigen-delivery system for induction of anti-pathogen's immune responses in the gut. 2017 , 8, 511-519		5
90	Selection of new lactic acid bacteria strains bearing probiotic features from mucosal microbiota of healthy calves: Looking for immunobiotics through in vitro and in vivo approaches for immunoprophylaxis applications. 2017 , 200, 1-13		26
89	Non-conventional expression systems for the production of vaccine proteins and immunotherapeutic molecules. 2017 , 13, 947-961		33

88	The Use of Probiotics as Vaccine Vectors to Prevent Viral Infections. 2017 , 47-60		1
87	The Evolution of gene regulation research in <i>Lactococcus lactis</i> . 2017 , 41, S220-S243		29
86	Recombinant <i>Lactococcus lactis</i> expressing bioactive exendin-4 to promote insulin secretion and beta-cell proliferation in vitro. <i>Applied Microbiology and Biotechnology</i> , 2017 , 101, 7177-7186	5:7	12
85	In vitro characteristics of <i>Lactobacillus</i> spp. strains isolated from the chicken digestive tract and their role in the inhibition of <i>Campylobacter</i> colonization. 2017 , 6, e00512		24
84	An engineered food-grade <i>Lactococcus lactis</i> strain for production and delivery of heat-labile enterotoxin B subunit to mucosal sites. 2017 , 17, 25		9
83	Immunogenic Properties of <i>Lactobacillus plantarum</i> Producing Surface-Displayed Mycobacterium tuberculosis Antigens. 2017 , 83,		23
82	Advances in the genomics and metabolomics of dairy lactobacilli: A review. 2017 , 61, 33-49		81
81	Applications of Genetically Modified Immunobiotics with High Immunoregulatory Capacity for Treatment of Inflammatory Bowel Diseases. 2017 , 8, 22		29
80	Development of a counterselectable seamless mutagenesis system in lactic acid bacteria. 2017 , 16, 116		15
79	Development and evaluation of an efficient heterologous gene knock-in reporter system in <i>Lactococcus lactis</i> . 2017 , 16, 154		2
78	PilVax - a novel peptide delivery platform for the development of mucosal vaccines. 2018 , 8, 2555		10
77	Mucosal and systemic immune responses elicited by recombinant <i>Lactococcus lactis</i> expressing a fusion protein composed of pertussis toxin and filamentous hemagglutinin from <i>Bordetella pertussis</i> . 2018 , 120, 155-160		7
76	Synthetic Biology Approaches to Engineer Probiotics and Members of the Human Microbiota for Biomedical Applications. 2018 , 20, 277-300		56
75	Recombinant Mouse Osteocalcin Secreted by <i>Lactococcus lactis</i> Promotes Glucagon-Like Peptide-1 Induction in STC-1 Cells. 2018 , 75, 92-98		8
74	Genetic Tools for the Enhancement of Probiotic Properties. 2018 , 371-387		
73	Analysis of Immune Responses in Mice Orally Immunized with Recombinant pMG36e-SP-TSOL18/ and pMG36e-TSOL18/ Vaccines of. 2018 , 2018, 9262631		2
72	M cell-targeting strategy enhances systemic and mucosal immune responses induced by oral administration of nuclease-producing <i>L. lactis</i> . <i>Applied Microbiology and Biotechnology</i> , 2018 , 102, 10703-10711 ⁹	5:7	
71	Engineering Components of the S-Layer for Biotherapeutic Applications. 2018 , 9, 2264		12

70	Microbial Delivery Vehicles for Allergens and Allergen-Derived Peptides in Immunotherapy of Allergic Diseases. 2018 , 9, 1449		9
69	Development of oral drug delivery systems with probiotic bacteria in the future. 2018 , 33, 414-421		
68	Mucosal Vaccine Vectors: Immune Responses against Bacterial and Viral Antigens. 2018 , 3,		34
67	Live Bacterial Vectors-A Promising DNA Vaccine Delivery System. 2018 , 6,		16
66	Lactic Acid Bacteria for Delivery of Endogenous or Engineered Therapeutic Molecules. 2018 , 9, 1821		24
65	Genetics of Lactococci. 2019 , 7,		
64	Internalin AB-expressing recombinant Lactobacillus casei protects Caco-2 cells from Listeria monocytogenes-induced damages under simulated intestinal conditions. 2019 , 14, e0220321		9
63	Inactivated Carrying a Surface-Displayed Ag85B-ESAT-6 Fusion Antigen as a Booster Vaccine Against Infection. 2019 , 10, 1588		11
62	Comparison of eight Lactobacillus species for delivery of surface-displayed mycobacterial antigen. 2019 , 37, 6371-6379		10
61	Recombinant lactococcus lactis secreting viral protein 1 of enterovirus 71 and its immunogenicity in mice. 2019 , 41, 867-872		4
60	Current issues regarding the application of recombinant lactic acid bacteria to mucosal vaccine carriers. <i>Applied Microbiology and Biotechnology</i> , 2019 , 103, 5947-5955	5-7	8
59	Immune efficacy of a porcine circovirus type 2 vaccine purified using Gram-positive enhancer matrix surface display technology. 2019 , 127, 658-669		3
58	Genetically engineered probiotic Saccharomyces cerevisiae strains mature human dendritic cells and stimulate Gag-specific memory CD8 T cells ex vivo. <i>Applied Microbiology and Biotechnology</i> , 2019 , 103, 5183-5192	5-7	8
57	Alternative Methods of Vaccine Delivery: An Overview of Edible and Intradermal Vaccines. 2019 , 2019, 8303648		43
56	Effects of new technology on the current manufacturing process of yogurt-to increase the overall marketability of yogurt. 2019 , 108, 69-80		36
55	Targeting ideal oral vaccine vectors based on probiotics: a systematical view. <i>Applied Microbiology and Biotechnology</i> , 2019 , 103, 3941-3953	5-7	18
54	Genetics of Lactococci. 2019 , 461-481		
53	Oral immunization with recombinant Lactococcus lactis NZ9000 expressing human papillomavirus type 16 E7 antigen and evaluation of its immune effects in female C57BL/6 mice. 2019 , 91, 296-307		10

52	Lactic Acid Bacteria as a Live Delivery System for the in situ Production of Nanobodies in the Human Gastrointestinal Tract. 2019 , 9,	15
51	Comparative proteomic analysis of four biotechnological strains <i>Lactococcus lactis</i> through label-free quantitative proteomics. 2019 , 12, 265-274	7
50	Production of Omp16 protein fused to the human interleukin 2 in MG1363 toward developing a -based vaccine against brucellosis. 2020 , 66, 39-45	2
49	Mucosal delivery of live <i>Lactococcus lactis</i> expressing functionally active JlpA antigen induces potent local immune response and prevent enteric colonization of <i>Campylobacter jejuni</i> in chickens. 2020 , 38, 1630-1642	10
48	Expression of <i>Helicobacter pylori</i> CagL gene in <i>Lactococcus lactis</i> MG1363 and evaluation of its immunogenicity as an oral vaccine in mice. 2019 , 142, 103926	8
47	Adjuvant effects of killed <i>Lactobacillus casei</i> DK128 on enhancing T helper type 1 immune responses and the efficacy of influenza vaccination in normal and CD4-deficient mice. 2020 , 38, 5783-5792	2
46	Anchoring of heterologous proteins in multiple <i>Lactobacillus</i> species using anchors derived from <i>Lactobacillus plantarum</i> . 2020 , 10, 9640	3
45	Eosinophils are the main cellular targets for oral gene delivery using Lactic acid bacteria. 2020 , 38, 3330-3338	1
44	Protection against <i>Trichinella spiralis</i> in BALB/c mice via oral administration of recombinant <i>Lactobacillus plantarum</i> expressing murine interleukin-4. 2020 , 280, 109068	7
43	DNA Vaccines. 2021 ,	0
42	Combined use of lactic-acid-producing bacteria as probiotics and rotavirus vaccine candidates expressing virus-specific proteins. 2021 , 166, 995-1006	2
41	The Role of Mucosal Immunity and Recombinant Probiotics in SARS-CoV2 Vaccine Development. 2021 , 13, 1239-1253	8
40	as a Potential Adjuvant and Delivery System for the Development of SARS-CoV-2 Oral Vaccines. 2021 , 9,	7
39	<i>Lactococcus</i> -based vaccine against brucellosis: IgG immune response in mice with rOmp16-IL2 fusion protein. 2021 , 203, 2591-2596	0
38	Antilisterial Potential of Lactic Acid Bacteria in Eliminating <i>Listeria monocytogenes</i> in Host and Ready-to-Eat Food Application. 2021 , 12, 234-257	8
37	Cytoplasmic expression of a model antigen with M Cell-Targeting moiety in lactic acid bacteria and implication of the mechanism as a mucosal vaccine via oral route. 2021 , 39, 4072-4081	2
36	Construction of an Integrated mCherry Red Fluorescent Protein Expression System for Labeling and Tracing in WCFS1. 2021 , 12, 690270	1
35	Bioengineering of LAB vector expressing Haemolysin co-regulated protein (Hcp): a strategic approach to control gut colonization of <i>Campylobacter jejuni</i> in a murine model. 2021 , 13, 48	0

34	Engineered living biomaterials.	31
33	Immunogenicity of a recombinant <i>Lactobacillus casei</i> , surface-expressed HP mutant of <i>Clostridium perfringens</i> epsilon toxin and its protective responses in BALB/c mice. 2021 , 200, 173-179	
32	The construction of recombinant <i>Lactobacillus casei</i> expressing hemagglutinin-neuraminidase protein and its immune response in chickens. 2021 , 158, 105091	0
31	Recombinant Avian β -Defensin Produced by Food-Grade <i>Lactococcus</i> as a Novel and Potent Immunological Enhancer Adjuvant for Avian Vaccine. 2021 , 13, 1833-1846	0
30	Heterologous Expression and Delivery of Biologically Active Exendin-4 by <i>Lactobacillus paracasei</i> L14. 2016 , 11, e0165130	8
29	<i>Lactobacillus plantarum</i> producing a <i>Chlamydia trachomatis</i> antigen induces a specific IgA response after mucosal booster immunization. 2017 , 12, e0176401	20
28	SYNTHETIC BIOLOGY AS AN INSTRUMENT FOR DEVELOPMENT OF INNOVATIVE VACCINES FOR PROPHYLAXIS OF BACTERIAL INFECTIONS. 2016 , 105-115	
27	ADVANCEMENTS IN DEVELOPING ANTI-CAMPYLOBACTER VACCINE FOR POULTRY. 2019 , 58, 385-398	
26	Recombinant lactic acid bacteria as promising vectors for mucosal vaccination. 2021 , 1, 20210026	6
25	Cyclic peptide production from lactic acid bacteria (LAB) and their diverse applications. 2020 , 1-20	0
24	Main Features of DNA-Based Vectors for Use in Lactic Acid Bacteria and Update Protocols. 2021 , 2197, 285-304	0
23	: A New Strategy for Vaccination. 2017 , 9, 163-168	15
22	Probiotic activity traits in vitro and production of antimicrobial peptides by <i>Lactobacillaceae</i> isolates from pulque using <i>Lactobacillus acidophilus</i> NCFM as control.. 2022 , 1	0
21	Attacking the Intruder at the Gate: Prospects of Mucosal Anti SARS-CoV-2 Vaccines.. 2022 , 11,	1
20	Recombinant <i>Limosilactobacillus</i> (<i>Lactobacillus</i>) delivering nanobodies against <i>Clostridium perfringens</i> NetB and alpha toxin confers potential protection from necrotic enteritis.. 2022 , 11, e1270	1
19	Current challenges for modern vaccines and perspectives for novel treatment alternatives. 2022 , 70, 103222	0
18	Recombinant invasive <i>Lactobacillus plantarum</i> expressing the J subgroup avian leukosis virus Gp85 protein induces protection against avian leukosis in chickens.. <i>Applied Microbiology and Biotechnology</i> , 2021 , 106, 729	5.7
17	The Complex Role of Lactic Acid Bacteria in Food Detoxification. 2022 , 14, 2038	5

- 16 NOD2 signaling in CD11c + cells is critical for humoral immune responses during oral vaccination and maintaining the gut microbiome.. **2022**, 12, 8491
- 15 Plasmid-Based Gene Expression Systems for Lactic Acid Bacteria: A Review. **2022**, 10, 1132 1
- 14 Comparison of the Immunogenic Properties of Lactiplantibacillus plantarum Carrying the Mycobacterial Ag85B-ESAT-6 Antigen at Various Cellular Localizations. **2022**, 13, 0
- 13 Lactic acid bacteria and bacteriocins as biopreservatives. **2022**, 147-162
- 12 Holin-assisted bacterial recombinant protein export.
- 11 Use of genetically modified lactic acid bacteria and bifidobacteria as live delivery vectors for human and animal health. **2022**, 14, 2
- 10 Recombinant vaccines in 2022: a perspective from the cell factory. **2022**, 21, 1
- 9 Construction of recombinant Lactococcus expressing thymosin and interferon fusion protein and its application as an immune adjuvant. 0
- 8 Immunomodulatory action of Lactococcus lactis. **2022**, 0
- 7 Expression of heterologous heparan sulphate binding protein of Helicobacter pylori on the surface of Lactobacillus rhamnosus GG. **2023**, 13, 0
- 6 Recent advances in genetic tools for engineering probiotic lactic acid bacteria. **2023**, 43, 0
- 5 Oral and intranasal immunization with food-grade recombinant Lactococcus lactis expressing high conserved region of SARS-CoV-2 spike protein triggers mice's immunity responses. **2023**, 13, 100265 0
- 4 Preclinical developments in the delivery of protein antigens for vaccination. **2023**, 20, 367-384 0
- 3 Oral vaccination with novel Lactococcus lactis mucosal live vector-secreting Brucella lumazine synthase (BLS) protein induces humoral and cellular immune protection against Brucella abortus. **2023**, 205, 0
- 2 The Role of Genetically Engineered Probiotics for Treatment of Inflammatory Bowel Disease: A Systematic Review. **2023**, 15, 1566 0
- 1 Repression of Staphylococcus aureus and Escherichia coli by Lactiplantibacillus plantarum Strain AG10 in Drosophila melanogaster In Vivo Model. **2023**, 11, 1297 0